Join the Semaglutide group to help and get support from people like you.
Semaglutide News
WHO Updates List of Essential Medicines to Include GLP-1s
TUESDAY, Sept. 9, 2025 – The World Health Organization published updated editions of its Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc) to include new treatments...
FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S.
FRIDAY, Sept. 5, 2025 -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering ...
14 Percent of U.S. Adults Initiate GLP-1 Receptor Agonist After Bariatric Surgery
WEDNESDAY, Sept. 3, 2025 – Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published online Aug. 27 in...
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 – Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published online Aug. 28 in...
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 – Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient...
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With Obesity
TUESDAY, Aug. 26, 2025 – For adults with obesity, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced overall risk for cancer, including lower risks for endometrial,...
Semaglutide Not Linked to Increased Risk of Eye Disorders, Diabetic Retinopathy
MONDAY, Aug. 18, 2025 – For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review published online Aug. 14...
Wegovy Granted Accelerated Approval in the US for the Treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supp...
26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
THURSDAY, Aug. 14, 2025 – In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by...
GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
TUESDAY, Aug. 12, 2025 – For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic...
Study IDs Barriers to GLP-1 Receptor Agonist Use in Adolescents, Young Adults
THURSDAY, Aug. 7, 2025 – A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have...
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
TUESDAY, Aug. 5, 2025 – For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION),...
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 – Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published online July 21 in...
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 – For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 – Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2, Nonalcoholic Fatty Liver Disease